tiprankstipranks
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
US Market

Apellis Pharmaceuticals (APLS) Ownership - Who Owns Apellis Pharmaceuticals?

Compare
868 Followers

Apellis Pharmaceuticals (APLS) Ownership Overview

3.46%26.47%40.12%14.36%15.59%
40.12% Other Institutional Investors
14.36% ETFs
15.59% Public Companies and Individual Investors
The ownership structure of Apellis Pharmaceuticals (APLS) stock is a mix of institutional, retail, and individual investors. Approximately 80.94% of the company’s stock is owned by Institutional Investors, 3.46% is owned by Insiders, and 15.59% is owned by Public Companies and Individual Investors.
The ownership structure of Apellis Pharmaceuticals (APLS) stock is a mix of institutional, retail, and individual investors. Approximately 66.58% of the company’s stock is owned by Institutional Investors, 3.46% is owned by Insiders, and 14.36% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Feb 12, 2025
Mark Jeffrey Delong
Chief Business & Strat Officer
xxxxxxxxxxxxx
$10356
Jan 30, 2025
Mark Jeffrey Delong
Chief Business & Strat Officer
xxxxxxxxxxxxx
$10775
Jan 30, 2025
xxxxxxxxxxxxx
$24354
Jan 30, 2025
xxxxxxxxxxxxx
$20516

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,088,600Institution8.11%276,427,640
9,562,794Institution7.69%262,020,556
8,894,854Institution7.15%243,719,000
2,607,977Institution2.10%71,458,570
2,536,205Institution2.04%69,492,017
1,969,268Institution1.58%53,957,943
1,955,117Insider1.57%53,570,206
1,309,394Institution1.05%35,877,396
1,200,000Institution0.96%32,880,000
1,147,716Insider0.92%31,447,418

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
10,088,600Institution8.11%276,427,640
8,894,854Institution7.15%243,719,000
1,969,268Institution1.58%53,957,943
1,200,000Institution0.96%32,880,000
1,144,142Institution0.92%31,349,491
997,107Institution0.80%27,320,732
986,546Institution0.79%27,031,360
534,831Institution0.43%14,654,369
493,300Institution0.40%13,516,420
467,487Institution0.38%12,809,144

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,295,133Institution2.65%105,147,694
2,691,834Institution2.16%85,896,423
2,592,619Institution2.08%71,193,318
1,645,058Institution1.32%52,493,801
1,527,719Institution1.23%48,749,513
633,852Institution0.51%17,367,545
605,680Institution0.49%16,595,632
515,904Institution0.41%14,166,724
368,075Institution0.30%10,085,255
341,103Institution0.27%9,346,222

FAQ

Who Owns Apellis Pharmaceuticals Inc (APLS)?
According to the latest TipRanks data, approximately 40.12% of the company's stock is held by institutional investors, 3.46% is held by insiders, and 15.59% is held by retail investors.
    What percentage of Apellis Pharmaceuticals Inc (APLS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 40.12% of Apellis Pharmaceuticals Inc (APLS) stock is held by institutional investors.
      What percentage of Apellis Pharmaceuticals Inc (APLS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 15.59% of Apellis Pharmaceuticals Inc (APLS) stock is held by retail investors.
        Who owns the most shares of Apellis Pharmaceuticals Inc (APLS)?
        VANGUARD SPECIALIZED FUNDS owns the most shares of Apellis Pharmaceuticals Inc (APLS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis